Antidepressants: Past, Present and Future

  • Sheldon H. Preskorn
  • John P. Feighner
  • Christina Y. Stanga
  • Ruth Ross

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 157)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Basic Principles: Pharmacologic Science

    1. Front Matter
      Pages 1-1
    2. S. H. Preskorn, M. L. Catterson
      Pages 35-86
    3. M. J. Burke, S. H. Preskorn
      Pages 87-114
  3. Basic Principles: Clinical Science

    1. Front Matter
      Pages 115-115
    2. T. J. Connor, B. E. Leonard
      Pages 117-148
  4. Current Pharmacotherapy of Major Depressive Disorder

    1. Front Matter
      Pages 169-169
    2. S. H. Preskorn, R. Ross
      Pages 171-183
    3. M. Lader
      Pages 185-208
    4. S. H. Kennedy, A. Holt, G. B. Baker
      Pages 209-239
    5. S. H. Preskorn, R. Ross, C. Y. Stanga
      Pages 241-262
    6. S. H. Preskorn, R. Ross
      Pages 263-324
    7. D. Wheatley
      Pages 325-351
  5. Use of Antidepressants in Special Populations

    1. Front Matter
      Pages 353-353
    2. J. F. Bober, S. H. Preskorn
      Pages 355-378
    3. K. A. Yonkers, O. Brawman-Mintzer
      Pages 379-392
    4. S. Glover, W. F. Boyer
      Pages 393-420
    5. R. D. Alarcon
      Pages 421-446
    6. M. Trivedi, T. Bettinger, B. Kleiber
      Pages 447-488
    7. M. L. Wainberg, A. J. Kolodny, L. J. Siever
      Pages 489-515
  6. Future Directions in the Treatment of Major Depressive Disorder

    1. Front Matter
      Pages 517-517
    2. V. Garlapati, W. F. Boyer, J. P. Feighner
      Pages 565-582
  7. Back Matter
    Pages 597-615

About this book


This book is being published as we mark the end of the first 50 years of the modern antidepressant era. This era began with the chance discovery that tri- clic antidepressants and monoamine oxidase inhibitors had antidepressant p- perties. That discovery had three consequences. First, it brought simple and effective treatment to patients suffering from major depressive illnesses. Second, these discoveries, together with the discovery of lithium and chlorpromazine, began the remedicalization of psychiatry by making it clear that the treatment of many of the major psychiatric illnesses can be approached in the same way as other medical conditions. However, the most far-reaching effect was to provide the first clue as to what mechanisms might underlie antidepressant efficacy, a development that has led to an explosion in the number of available an- depressants and to their widespread use. The goal of this book is to provide a thorough review of the current status of antidepressants—how we arrived at this point in their evolution and where we are going in both the near and the long term. The book employs both a scientific and historical approach to accomplish these goals. The book is intended for practitioners who use antidepressants on a daily basis in their practice as well as for the student and researcher. Each will find that the book provides a comprehensive and logical approach to this important group of medications. The importance of the book is a function of its topic.


antidepressants brain depression depressive disorder drug drug development genomics kinetics personality pharmacokinetics pharmacotherapy population psychiatry research serotonin

Editors and affiliations

  • Sheldon H. Preskorn
    • 1
  • John P. Feighner
    • 2
  • Christina Y. Stanga
    • 3
  • Ruth Ross
    • 4
  1. 1.Department of Psychiatry and Behavioral SciencesUniversity of Kansas School of Medicine and Psychiatric Research Insitute1010 N. KansasWichitaUSA
  2. 2.Feighner Research InstituteSan DiegoUSA
  3. 3.NeillsvilleUSA
  4. 4.Ross EditorialIndependenceUSA

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2004
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-62135-2
  • Online ISBN 978-3-642-18500-7
  • Series Print ISSN 0171-2004
  • Series Online ISSN 1865-0325
  • Buy this book on publisher's site
Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods